The Impact of China's Human Genetic Resources Regime on Biopharma MNCs

China's HGR regime has been significantly bolstered in the last two years, delaying the research and development activities of biopharma MNCs in the country

12 minute readMay 14, 2021 at 03:08 AM

Vincent Chow

The Impact of China's Human Genetic Resources Regime on Biopharma MNCs

Nikita G. Sidorov/iStockphoto.com

Multinational pharmaceutical companies are reducing research and development activity in China as the government tightens access to human genetic resources (HGR) and imposes ownership control on intellectual property.

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

✓ A database of 3000+ essential documents, including key PRC laws translated into English
✓ Newsletters with business-critical and sector-specific updates
✓ Premium mobile access with timely analysis on China's fast-changing market

Already a Subscriber? Log In. Sign In Now

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)